Pharmaceuticals

I Peace manufactures 100 lines of GMP iPS Cells cumulatively

Proof of customer recognition of its quality and mass manufacturing capability PALO ALTO, Calif., Dec. 30, 2024 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://ipeace.com/en/ ), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell ther...

2024-12-31 04:24 1172

Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SEONGNAM, South Korea and BOSTON, Dec. 30, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that James Jungkue Lee, Founder and CEO of Bridge Biotherapeutics, will present ...

2024-12-30 23:00 2238

CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)

SHANGHAI, Dec. 30, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the positive results from the pivotal Phase II clinical trial CT041-...

2024-12-30 21:50 2160

Huadong Medicine Co., Ltd. and SynerK reached a strategic cooperation to jointly develop a novel siRNA drug SNK-2726

SUZHOU, China, Dec. 30, 2024 /PRNewswire/ -- Hangzhou Sino-US Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine"), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), and SynerK PharmaTech (Suzhou) Co., Ltd. (hereinafter referred to as "SynerK") have reache...

2024-12-30 13:00 1590

Matwings Technology Raised Series A Funding of Tens of Millions USD to Redefine Protein Design

'Beyond Structure, Predicting Function' SHANGHAI, Dec. 25, 2024 /PRNewswire/ -- Recently, Shanghai Matwings Technology Co., Ltd. ('Matwings'), a global leader in AI-driven protein design, announced the successful completion of Series A funding rounds, raising tens of millions of USD, led by Qimi...

2024-12-26 11:07 1565

Haikou delivers mix of tradition and cutting-edge industry

BEIJING, Dec. 25, 2024 /PRNewswire/ -- A news report from China Daily:    Haikou, capital of South China’s Hainan province, is a vibrant metropolis known for its bustling ports, golden beaches and profound culture. Join Michael and Ani on a scavenger hunt in Haikou to explore its unique charm! F...

2024-12-26 10:07 1817

Preliminary Results of Qilu Pharmaceutical's Phase Ia Study on GPRC5D/CD3-Targeting Bispecific Antibody QLS32015 Unveiled at 2024 ASH Annual Meeting

JINAN, China, Dec. 25, 2024 /PRNewswire/ -- During the 66th Annual Meeting of the American Society of Hematology (ASH) held inSan Diego from December 7 to 10 , preliminary results from the first human trial of QLS32015, a novel anticancer drug developed by Qilu Pharmaceutical for treating relapse...

2024-12-25 15:42 2498

Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALS

NANTONG and SUZHOU, China, Dec. 24, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosing of the first patient in the Phase I clinical trial of RAG-17, an innovative siRNA t...

2024-12-24 20:00 2881

Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis

CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") ofChina has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody, trade nam...

2024-12-23 22:31 2004

Porton Pharma Solutions and Dragon Sail Pharmaceutical Form Strategic Partnership to Build a New Ecosystem for ADC Drug Development, Production, and Supply Chain

CHONGQING, China, Dec. 23, 2024 /PRNewswire/ -- On December 20, 2024, Porton Pharma Solutions (hereinafter referred to as "company" or "Porton") and Dragon Sail Pharmaceutical (Shanghai) Co., Ltd. (a subsidiary of Guilin Sanjin, hereinafter referred to as "Dragon Sail Pharmaceutical") formally si...

2024-12-23 21:00 1988

Aptamer developed by HKBU for treating rare bone disease 'X-linked hypophosphatemia' receives Orphan Drug Designation and Rare Pediatric Disease Designation by U.S. FDA

HONG KONG, Dec. 23, 2024 /PRNewswire/ -- A research led by Hong Kong Baptist University (HKBU) and the Shanghai Sixth People's Hospital Affiliated to School of Medicine at Shanghai Jiao Tong University (Shanghai Sixth People's Hospital) has discovered that an aptamer developed by HKBU can be used...

2024-12-23 13:26 1532

CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody

SHANGHAI, Dec. 22, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced today the submission of clinical trial application inAustralia for CS2009 (PD-1/VEGF/CT...

2024-12-23 08:00 1714

YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR

SHANGHAI, Dec. 21, 2024 /PRNewswire/ -- YolTech Therapeutics today announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201, a first-in-class CRISPR/Cas9-based in vivo gene-editing therapy for ATTR amyloidosis. The trial has completed dosing in eight participants, including ...

2024-12-21 16:23 3471

United Imaging Intelligence at RSNA 2024: Empowering a More Intelligent and Connected World with Medical AI

CHICAGO, Dec. 20, 2024 /PRNewswire/ -- As RSNA 2024 concluded, United Imaging Intelligence (UII), a subsidiary of United Imaging Group specializing in medical AI, made a significant impression with a visionary showcase that seamlessly aligned with the event's theme: "Building Intelligent Connecti...

2024-12-20 22:00 1502

Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer

BOSTON, Dec. 20, 2024 /PRNewswire/ -- Medicilon, a leading preclinical contract research organization (CRO), has named Dr.Lilly Xu as its new Chief Technology Officer (CTO). With over30 years of experience in preclinical drug development, Dr. Xu will lead Medicilon's technological innovation a...

2024-12-20 21:30 1367

LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

* Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY * Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY * Gross margin increased to 82.6% from 80.9% in the same period of FY2024 * Total operating expenses decreased to RMB 276.4 million, down 31.6%...

2024-12-19 22:05 3172

BGM Group and Jointown Deepen Cooperation, Ushering in a New Era of Pharmaceutical Development

CHENGDU, China, Dec. 19, 2024 /PRNewswire/ -- BGM Group Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), Mr. Xin Zhanchang, Chairman of the Board of Directors of BGM Group and Chairman of Gansu Qilianshan Pharmaceutical Co., Ltd., led the sales team to visit their long-term strategic partner, Jointow...

2024-12-19 21:30 1612

LG Corp. Chairman and CEO Kwang Mo Koo sends 2025 New Year Address to 270,000 global employees on December 19

* "Let's Shape LG's Future with the DNA of Challenge and Change We've had Since Day 1" * Highlighting LG's Spirit – the DNA of challenge and change since Day 1 -        "LG's Day 1 spirit of choosing what others wouldn't dare comes from our DNA of challenge and change as we serve our customer...

2024-12-19 13:00 1351

Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare

SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a pioneer in Internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb ("BMS")China on December 16th. The partnership was officially formalized with the signing of a colla...

2024-12-19 12:40 1129

Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical

Highlights * Clarity has developed a proprietary fibroblast activation protein (FAP)-targeted radiopharmaceutical product that can be used with the perfect pairing of copper isotopes for the diagnosis and treatment of cancer. * The product, termed SAR-bisFAP, has shown strong tumour targeting...

2024-12-18 22:03 1489
123456 ... 131